Role of CIP2A in the antitumor effect of bortezomib in colon cancer

Ding,Yayun; Wang,Yueguo; Ju,Shaoqing; Wu,Xinghua; Zhu,Wencai; Shi,Feng; Mao,Liping

doi:10.3892/mmr.2014.2173

Role of CIP2A in the antitumor effect of bortezomib in colon cancer

Authors:
- Yayun Ding
- Yueguo Wang
- Shaoqing Ju
- Xinghua Wu
- Wencai Zhu
- Feng Shi
- Liping Mao
View Affiliations

Affiliations: Department of Laboratory Medicine, Nantong University, Nantong, Jiangsu 226001, P.R. China, Laboratory Department, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Surgical Comprehensive Laboratory, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Laboratory Department, Nantong Third People's Hospital, Nantong, Jiangsu 226001, P.R. China
Published online on: April 24, 2014 https://doi.org/10.3892/mmr.2014.2173
Pages: 387-392

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A) has been identified as an oncoprotein that is able to promote the proliferation of cancer cells. The role of CIP2A in the anticancer activity of bortezomib in colon cancer remains to be elucidated. In the present study, the antitumor effect of bortezomib was investigated and the role of CIP2A in determining the effect on colon cancer cells was identified. In the present study, bortezomib demonstrated an antitumor effect, as observed by WST‑1 assay and flow cytometry. In addition, the mRNA and protein level of CIP2A was inhibited in a dose‑dependent manner by bortezomib with quantitative PCR (qPCR) and western blotting. Furthermore, the inhibition of CIP2A with small interfering RNA by treatment with bortezomib inhibited proliferation, increased apoptosis and attenuated the invasion of the cells. Finally, the in vivo data demonstrated that bortezomib was able to decrease the growth of tumors, and that CIP2A was downregulated in the LoVo tumors treated with bortezomib. Therefore, CIP2A was shown to be important in the bortezomib‑induced inhibitory effect on colon cancer.

View Figures

View References

1	Naishadham D, Lansdorp-Vogelaar I, Siegel R, Cokkinides V and Jemal A: State disparities in colorectal cancer mortality patterns in the United States. Cancer Epidemiol Biomarkers Prev. 20:1296–1302. 2011. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J clin. 61:69–90. 2011. View Article : Google Scholar
3	Center MM, Jemal A and Ward E: International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 18:1688–1694. 2009. View Article : Google Scholar : PubMed/NCBI
4	Ferrari P, Jenab M, Norat T, et al: Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 121:2065–2072. 2007. View Article : Google Scholar : PubMed/NCBI
5	Adams J and Kauffman M: Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22:304–311. 2004. View Article : Google Scholar
6	Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 23:667–675. 2005.
7	O’Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the novel proteasome inhibitor Bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 23:676–684. 2005.PubMed/NCBI
8	Orlowski RZ and Baldwin AS Jr: NF-kappaB as a therapeutic target in cancer. Trends Mol Med. 8:385–389. 2002. View Article : Google Scholar : PubMed/NCBI
9	Orlowski RZ and Kuhn DJ: Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 14:1649–1657. 2008. View Article : Google Scholar : PubMed/NCBI
10	Voorhees PM and Orlowski RZ: The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol. 46:189–213. 2006. View Article : Google Scholar : PubMed/NCBI
11	QI W, White MC, Choi W, Guo C, Dinney C, McConkey DJ and Siefker-Radtke A: Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells. PLoS One. 8:e695092013. View Article : Google Scholar : PubMed/NCBI
12	Cagnetta A, Cea M, Calimeri T, et al: Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. Blood. 122:1243–1255. 2013.
13	Tseng LM, Liu CY, Chan KC, Chu PY, Shiau CW and Chen KF: CIP2A is a target of Bortezomib in human triple negative breast cancer cells. Breast Cancer Res. 14:R682012. View Article : Google Scholar : PubMed/NCBI
14	Lin YC, Chen KC, Chen CC, Cheng AL and Chen KF: CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol. 48:585–593. 2012. View Article : Google Scholar : PubMed/NCBI
15	Liu CY, Shiau CW, Kuo HY, Huang HP, Chen MH, Tzeng CH and Chen KF: Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. Haematologica. 98:729–738. 2013. View Article : Google Scholar : PubMed/NCBI
16	Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ and Cheng AL: CIP2A mediates effect of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene. 29:6257–6266. 2010. View Article : Google Scholar : PubMed/NCBI
17	Junttila MR, Puustinen P, Niemelä M, et al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62. 2007. View Article : Google Scholar : PubMed/NCBI
18	Li W, Ge Z, Liu C, Björkholm M, Jia J and Xu D: CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 14:3722–3728. 2008. View Article : Google Scholar : PubMed/NCBI
19	Böckelman C, Koskensalo S, Hagström J, Lundin M, Ristimäki1 A and Haglund C: CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther. 13:289–295. 2012.PubMed/NCBI
20	Côme C, Laine A, Chanrion M, et al: CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 15:5092–5100. 2009.PubMed/NCBI
21	Kulp SK, Yang YT, Hung CC, et al: 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 64:1444–1451. 2004. View Article : Google Scholar : PubMed/NCBI
22	Chen KF, Yeh PY, Yeh KH, et al: Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 68:6698–6707. 2008. View Article : Google Scholar : PubMed/NCBI
23	Vaarala MH, Väisänen MR and Ristimäki A: CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res. 29:1362010. View Article : Google Scholar : PubMed/NCBI
24	Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ and Wang EH: CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 18:857–865. 2011. View Article : Google Scholar : PubMed/NCBI
25	Coenen EA, Zwaan CM, Meyer C, et al: KIAA1524: a novel MLL translocation partner in acute myeloid leukemia. Leuk Res. 35:133–135. 2011. View Article : Google Scholar : PubMed/NCBI
26	Khanna A, Böckelman C, Hemmes A, et al: MYC-dependent regulation and prognostic, role of CIP2A in gastric cancer. J Natl Cancer Inst. 101:793–805. 2009. View Article : Google Scholar : PubMed/NCBI
27	Yi F, Ni W, Bai J and Li W: Expression and biological role of CIP2A in human astrocytoma. Mol Med Rep. 7:1376–1380. 2013.PubMed/NCBI
28	Huang LP, Savoly D, Sidi AA, Adelson ME, Mordechai E and Trama JP: CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Med. 1:76–81. 2012. View Article : Google Scholar : PubMed/NCBI
29	Böckelman C, Lassus H, Hemmes A, et al: Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer. 105:989–995. 2011.
30	Teng HW, Yang SH and Lin JK: CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg. 16:1037–1047. 2012. View Article : Google Scholar : PubMed/NCBI
31	Pitts TM, Morrow M, Kaufman SA, Tentler JJ and Eckhardt SG: Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther. 8:342–349. 2009. View Article : Google Scholar : PubMed/NCBI
32	Choi YA, Park JS, Park MY, et al: Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett. 585:755–760. 2011. View Article : Google Scholar : PubMed/NCBI